Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

被引：17
作者：
Bhatt A. [1 ]
Goéré D. [2 ]
机构：
[1] Department of Surgical Oncology, Fortis Hospital, 154/9 Bannerghatta road, Opposite IIM-Bangalore, Bangalore
[2] Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Villejuif
来源：
Indian Journal of Surgical Oncology | 2016年 / 7卷 / 2期
关键词：
Colorectal Cancer; Cytoreductive surgery; HIPEC; Peritoneal Metastases;
D O I：
10.1007/s13193-016-0499-z
中图分类号：
学科分类号：
摘要：
Occurring either synchronously or metachronously to the primary tumor, peritoneal metastases (PM) are diagnosed in 8 to 20 % of the patients with colorectal cancer (CRC). Prognosis of these patients appears to be worse than those with other sites of metastases. While systemic therapy has shown significant prolongation of survival in patients with stage IV colorectal cancer, the outcomes in the subset of patients with PM has been much inferior. Over the last 2 decades, cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have been effective in substantially prolonging survival in patients with colorectal PM and have the potential to cure certain patients as well. This article reviews the current evidence for CRS and HIPEC to treat colorectal PM as well as future research going on in this form of locoregional treatment. © 2016, Indian Association of Surgical Oncology.
引用
收藏
页码：177 / 187
页数：10
相关论文
共 85 条
[11]  
Galandiuk S., Wieand H.S., Moertel C.G., Cha S.S., Fitzgibbons R.J., Pemberton J.H., Wolff B.G., Patterns of recurrence after curative resection of carcinoma of the colon and rectum, Surg Gynecol Obstet, 174, pp. 27-32, (1992)
[12]  
Russell A.H., Tong D., Dawson L.E., Wisbeck W.M., Griffin T.W., Laramore G.E., Luk K.H., Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone, Int J Radiat Oncol Biol Phys, 9, 3, pp. 361-365, (1983)
[13]  
Russell A.H., Tong D., Dawson L.E., Wisbeck W., Adenocarcinoma of the proximal colon. sites of initial dissemination and patterns of recurrence following surgery alone, Cancer, 53, 2, pp. 360-367, (1984)
[14]  
Jayne D.G., Fook S., Loi C., Seow-Choen F., Peritoneal carcinomatosis from colorectal cancer, Br J Surg, 89, 12, pp. 1545-1550, (2002)
[15]  
Ihemelandu C., Shen P., Stewart J., Votanopoulos K., Levine A., Management Of Peritoneal Carcinomatosis from colorectal cancer, Semin Oncol, 38, 4, pp. 568-575, (2011)
[16]  
Esquivel J., Current Status and Future Directions of Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Intervent Oncol 360
[17]  
2(6), pp. E45-E52, (2014)
[18]  
Goldberg R.M., Sargent D.J., Morton R.F., A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, pp. 23-30, (2004)
[19]  
Hurwitz H., Fehrenbacher L., Novotny W., Et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 23, pp. 2335-2342, (2004)
[20]  
Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., Koski S., Lichinitser M., Yang T.S., Rivera F., Couture F., Sirzen F., Cassidy J., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study, J Clin Oncol, 26, 12, pp. 2013-2019, (2008)
123456789